Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Down 14.1% Since Last Earnings Report: Can It Rebound?

Ascendis Pharma

Cara Therapeutics

Sesen Bio Inc.

Sanofi

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates

Health Canada has approved Jazz Pharmaceuticals plc's (NASDAQ: JAZZ) Sunosi (solriamfetol) for excessive daytime sleepiness (EDS) associated with narcolepsy or obstructive sleep apnea (OSA) in adult patients.  Once-daily Sunosi is approved with doses of 75 mg and 150 mg.

Canada Approves Jazz Pharma's Excessive Daytime Sleepiness Med

22nd Century Group

Neither of them needs to sell marijuana to consumers to succeed.

Got $4,000? Buy These 2 Cannabis-Focused Biotech Stocks

Pubmatic

Trupanion

Bargains abound, even with the stock market near an all-time high.

The Smartest Stocks to Buy With $600 Right Now

AbbVie

Could These Be Good Long Term Investments For Your Portfolio? The post Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Best Medical Marijuana Stocks To Buy In 2021? 2 Possible Long Term Investments Right Now

Investors have been selling off the stock since the company released its earnings report earlier this month.

This Cannabis Stock Is Full of Potential and Hasn't Been This Cheap in Months

Agrify

Anebulo Pharmaceuticals

Clever Leaves Holdings Inc

Greenlane Holdings

Hydrofarm Holdings Group

Akerna Corp

Merida Merger

Scotts Miracle-Gro

Turning Point Brands

Urban-gro

Village Farms International

cbdMD Inc

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

A Week's Worth of Actionable Cannabis Stock News

Jazz's (JAZZ) Xywav gets FDA approval for new indication, idiopathic hypersomnia. Following approval, Xywav becomes the first drug for treatment of this sleep disorder.

Jazz's (JAZZ) Xywav Gets FDA Nod for Idiopathic Hypersomnia

DUBLIN, Aug. 12, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of idiopathic hypersomnia in adults.1 The company plans to make Xywav available to patients with idiopathic hypersomnia later this year following Risk Evaluation and Mitigation Strategies (REMS) implementation. "We are excited that with today's approval Xywav will become the first and only medicine indicated to treat idiopathic hypersomnia, a unique medical condition that can have significant effects on the lives of those diagnosed with the condition," said Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals.

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

Jazz's (JAZZ) unit GW Pharmaceuticals' Epidyolex (cannabidiol) gets a regulatory nod for a new indication in the United Kingdom. Following this announcement, stock prices fell.

Jazz's (JAZZ) Epidyolex Gets Approval for New Indication in UK

Builders FirstSource

Colfax

Ciena

II-VI Incorporated

Lumentum Holdings

Neurocrine Biosciences

Papa John's

Signature Bank

Targa Resources

XPO Logistics

Want more stability and greater growth prospects in your investments? These top-rated mid-cap stocks offer the best of both worlds.

11 Mighty Mid-Cap Stocks for the Rest of 2021

LOS ANGELES, Aug. 10, 2021 /PRNewswire/ -- Stand Up To Cancer® (SU2C) and Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announce a three-year, $4 million research collaboration to explore new opportunities, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers. The collaboration also includes digital ethnography research to identify barriers to treatment and to gain insights and perspectives about small cell lung cancer (SCLC) from patients and caregivers in underserved communities.

Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers

LONDON, Aug. 10, 2021 /PRNewswire/ -- GW Pharmaceuticals ("GW"), a world leader in discovering, developing and delivering regulatory approved cannabis-based medicines and now part of Jazz Pharmaceuticals plc (Nasdaq: JAZZ), today announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a new indication for GW's cannabidiol as an adjunctive treatment of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older. GW was initially granted marketing authorisation for this medicine in the UK in September 2019 as an adjunctive therapy for seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients two years of age and older.

GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex

Canopy Growth

Cronos Group

Innovative Industrial Properties

Tilray Brands

Your Weekly Hit of Cannabis Stocks on the Move

Jazz Pharma's (JAZZ) product revenues grow in the second quarter on the back of strong demand for its new drugs and additional sales from drugs added with the acquisition of GW Pharmaceuticals.

Jazz Pharma (JAZZ) Q2 Earnings Beat, Sales Ride on GW Buyout

Jazz Pharmaceuticals' (JAZZ) CEO Bruce Cozadd on Q2 2021 Results - Earnings Call Transcript

Jazz (JAZZ) delivered earnings and revenue surprises of 9.86% and 1.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Tops Q2 Earnings and Revenue Estimates

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 5.12% over the past year to $3.90, which beat the estimate of $3.42.

Recap: Jazz Pharmaceuticals Q2 Earnings

DUBLIN, Aug. 3, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2021 and affirmed non-GAAP adjusted financial guidance for 2021. "As we enter what we expect to be a period of sustained growth, I have never been more excited about the future for Jazz.

Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results

Jazz Pharmaceuticals (NASDAQ:JAZZ) releases its next round of earnings this Tuesday, August 03. Get the latest predictions in Benzinga's essential guide to the company's Q2 earnings report.

Jazz Pharmaceuticals's Earnings: A Preview

EINDHOVEN, Netherlands--(BUSINESS WIRE)--Onera Health, a leader in sleep diagnostic and monitoring solutions, closed the Series B funding round today, which brought the total funding raised to date above the €24M mark. Led by Innovation Industries in close collaboration with Invest-NL and with existing investors Jazz Pharmaceuticals, imec.xpand, BOM and 15th Rock, the company intends to use the funds to execute clinical studies and further commercialize its sleep diagnostics and monitoring prod

Onera raises €10.5M in Series B funding

Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jazz Pharmaceuticals (JAZZ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Jazz Pharma is not the most popular drugmaker, but it is definitely worth a second look.

Is Jazz Pharmaceuticals Stock a Buy?

DUBLIN, July 22, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the National Comprehensive Cancer Network® (NCCN) added Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to the Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia (ALL), for both pediatric and adult patients. The NCCN Guidelines for ALL and the NCCN Guidelines for Pediatric ALL now include asparaginase erwinia chrysanthemi (recombinant)-rywn as a treatment option for patients with hypersensitivity to E.

National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia

News for Jazz Pharmaceuticals Stock (JAZZ)